Beta-Blocker Efficacy After Myocardial Infarction, Stratified by Ejection Fraction

A 40.7 KB document by Shujuan Zhao, last updated in April 2026, summarizes evidence on beta-blocker therapy for post-MI patients. It pools data from three randomized controlled trials and two meta-analyses, finding no benefit for patients with preserved LVEF but a 25% relative risk reduction for those with mildly reduced LVEF. The document supports an ejection-fraction-stratified approach to long-term beta-blocker use in contemporary practice.

Use Cases

• Inform clinical guideline development based on the summarized trial evidence and meta-analyses.
• Support evidence-based decision-making for prescribing beta-blockers based on patient ejection fraction.
• Identify knowledge gaps in post-MI therapy as highlighted in the document's critical appraisal.

Strengths

• Summarizes evidence from three randomized controlled trials and two contemporary meta-analyses.
• Provides specific quantitative findings, such as a 25% relative risk reduction for patients with LVEF 40%-49% and no benefit for LVEF ≥50%.
• Critically appraises trial designs and outcomes stratified by left ventricular ejection fraction.

Limitations

• The dataset is a 40.7 KB DOCX document, indicating a very limited scope of structured data.
• Row count and column-level documentation are absent; the content is textual analysis rather than a primary data table.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare, author Shujuan Zhao

Collection Method

Evidence summary and critical appraisal of published randomized controlled trials and meta-analyses.

Freshness

Last updated 2026-04-21 05:25:55